Maintenance olaparib (Lynparza) appeared to be associated with an overall survival benefit vs placebo in women with platinum-sensitive serous ovarian cancer and BRCA1 andBRCA2 mutations, according to an updated analysis of a phase II trial reported in The Lancet Oncology by Ledermann et al. Maintenance olaparib was previously reported to significantly prolong progression-free survival in the study.
In the Canadian phase III PANCREOX trial reported in theJournal of Clinical Oncology, Gill et al found no benefit of modified FOLFOX6 (infusional fluorouracil [5-FU], leucovorin, and oxaliplatin) vs infusional 5-FU/leucovorin as second-line treatment in patients with advanced pancreatic cancer who had received gemcitabine-based chemotherapy.
Hodi et al found “encouraging survival outcomes” with the addition of nivolumab to ipilimumab in patients with previously untreated unresectable stage III or IV melanoma, according to 2-year overall survival data in the phase II CheckMate 069 trial. These results were reported in The Lancet Oncology.
The ASCO Post
Results from the phase III RESORCE trial show that regorafenib (Stivarga) tablets achieved a median overall survival improvement in patients with unresectable hepatocellular carcinoma that progressed after treatment with sorafenib (Nexavar) tablets. The study, presented by Jordi Bruix, MD, et al during the European Society of Medical Oncology (ESMO) 18th World Congress on Gastrointestinal Cancer in Barcelona,1 found that patients taking regorafenib had a median overall survival of 10.6 months vs 7.8 months for placebo plus best supportive care (hazard ratio [HR], 0.62; 95% confidence interval[CI], 0.50–0.78; P < .001).
The ASCO Post
New research links specific inherited genetic alterations to an increased risk for uveal melanoma, a rare form of melanoma that arises from pigment cells that determine eye color. These findings were published by Ferguson et al inScientific Reports. Previous clinical data suggests uveal melanoma is more common in Caucasians and individuals with light eye coloration; however, the genetic mechanisms underlying this cancer's development were largely unknown.